<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
      <PMID Version="1">35606782</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1478-6362</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Arthritis research &amp; therapy</Title>
          <ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren's syndrome-associated interstitial lung disease.</ArticleTitle>
        <Pagination>
          <StartPage>121</StartPage>
          <MedlinePgn>121</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-022-02811-z</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. 56443961@qq.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Hong-Xia</ForeName>
            <Initials>HX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Xiao-Lei</ForeName>
            <Initials>XL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Mental Health, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. sydey_hxl@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Yu-Ping</ForeName>
            <Initials>YP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Guang-Ying</ForeName>
            <Initials>GY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Arthritis Res Ther</MedlineTA>
        <NlmUniqueID>101154438</NlmUniqueID>
        <ISSNLinking>1478-6354</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Interstitial lung disease (ILD)</Keyword>
        <Keyword MajorTopicYN="N">Primary Sjogren syndrome (pSS)</Keyword>
        <Keyword MajorTopicYN="N">Th1/Th2 ratio</Keyword>
        <Keyword MajorTopicYN="N">Th2 cells</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>23</Hour>
          <Minute>48</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35606782</ArticleId>
        <ArticleId IdType="doi">10.1186/s13075-022-02811-z</ArticleId>
        <ArticleId IdType="pii">10.1186/s13075-022-02811-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Efared B, Ebang-Atsame G, Rabiou S, et al. The diagnostic value of the bronchoalveolar lavage in interstitial lung diseases. J Negat Results Biomed. 2017;16(1):4. https://doi.org/10.1186/s12952-017-0069-0 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12952-017-0069-0</ArticleId>
            <ArticleId IdType="pubmed">28245857</ArticleId>
            <ArticleId IdType="pmc">5331687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther. 2010;12(4):213. https://doi.org/10.1186/ar3097 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar3097</ArticleId>
            <ArticleId IdType="pubmed">20735863</ArticleId>
            <ArticleId IdType="pmc">2945045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amoura Z, Duhaut P, Huong DL, et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1279–82. https://doi.org/10.1158/1055-9965.EPI-04-0624 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1055-9965.EPI-04-0624</ArticleId>
            <ArticleId IdType="pubmed">15894686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjogren’s syndrome. Ann Rheum Dis. 2000;59(9):709–12. https://doi.org/10.1136/ard.59.9.709 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.59.9.709</ArticleId>
            <ArticleId IdType="pubmed">10976085</ArticleId>
            <ArticleId IdType="pmc">1753261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819. https://doi.org/10.1136/bmj.h6819 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.h6819</ArticleId>
            <ArticleId IdType="pubmed">26912511</ArticleId>
            <ArticleId IdType="pmc">6887350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong X, Zhou J, Guo X, et al. A Retrospective analysis of distinguishing features of chest hrct and clinical manifestation in primary Sjogren’s syndrome-related interstitial lung disease in a Chinese population. Clin Rheumatol. 2018;37(11):2981–8. https://doi.org/10.1007/s10067-018-4289-6 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-018-4289-6</ArticleId>
            <ArticleId IdType="pubmed">30242640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta S, Ferrada MA, Hasni SA. Pulmonary manifestations of primary Sjogren’s syndrome: underlying immunological mechanisms, clinical presentation, and management. Front Immunol. 2019;10:1327. https://doi.org/10.3389/fimmu.2019.01327 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01327</ArticleId>
            <ArticleId IdType="pubmed">31249572</ArticleId>
            <ArticleId IdType="pmc">6583234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the Eular Scleroderma Trials and Research (Eustar) database. Ann Rheum Dis. 2010;69(10):1809–15. https://doi.org/10.1136/ard.2009.114264 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2009.114264</ArticleId>
            <ArticleId IdType="pubmed">20551155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, Zheng XJ, Ji YL, et al. Tumour markers in rheumatoid arthritis-associated interstitial lung disease. Clin Exp Rheumatol. 2016;34(4):587–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27213221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandler DB, Hyde DM, Giri SN. Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am J Pathol. 1983;112(2):170–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6192723</ArticleId>
            <ArticleId IdType="pmc">1916255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thrall RS, Barton RW. A comparison of lymphocyte populations in lung tissue and in bronchoalveolar lavage fluid of rats at various times during the development of bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis. 1984;129(2):279–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6198943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the Minor salivary gland infiltrates in Sjogren’s syndrome. J Autoimmun. 2010;34(4):400–7. https://doi.org/10.1016/j.jaut.2009.10.004 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2009.10.004</ArticleId>
            <ArticleId IdType="pubmed">19889514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao M, Hao Z, Guo Y, et al. Short-term and low-dose Il-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjogren’s syndrome. Ann Rheum Dis. 2018;77(12):1838–40. https://doi.org/10.1136/annrheumdis-2018-213036 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2018-213036</ArticleId>
            <ArticleId IdType="pubmed">29936436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren’s syndrome: a revised version of the european criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8. https://doi.org/10.1136/ard.61.6.554 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.61.6.554</ArticleId>
            <ArticleId IdType="pubmed">12006334</ArticleId>
            <ArticleId IdType="pmc">1754137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League against Rheumatism Classification Criteria for Primary Sjogren’s Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9–16. https://doi.org/10.1136/annrheumdis-2016-210571 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2016-210571</ArticleId>
            <ArticleId IdType="pubmed">27789466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raghu G, Collard HR, Egan JJ, et al. An Official Ats/Ers/Jrs/Alat Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. https://doi.org/10.1164/rccm.2009-040GL .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.2009-040GL</ArticleId>
            <ArticleId IdType="pubmed">21471066</ArticleId>
            <ArticleId IdType="pmc">5450933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Li M. 2018 Chinese expert-based consensus statement regarding the diagnosis and treatment of interstitial lung disease associated with connective tissue diseases. Chi J Intern Med. 2018;57(8):558–65. https://doi.org/10.3760/cma.j.issn.0578-1426.2018.08.005 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3760/cma.j.issn.0578-1426.2018.08.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Zhang SX, Hao YF, et al. The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2. Ther Adv Chronic Dis. 2020;11:1–12. https://doi.org/10.1177/2040622320916014 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2040622320916014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi L, Han XL, Guo HX, et al. Increases in tumor markers are associated with primary Sjogren’s syndrome-associated interstitial lung disease. Ther Adv Chronic Dis. 2020;11:2040622320944802. https://doi.org/10.1177/2040622320944802 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2040622320944802</ArticleId>
            <ArticleId IdType="pubmed">32843956</ArticleId>
            <ArticleId IdType="pmc">7418474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enomoto Y, Takemura T, Hagiwara E, et al. Prognostic factors in interstitial lung disease associated with primary Sjogren’s syndrome: a retrospective analysis of 33 pathologically-proven cases. PLoS One. 2013;8(9):e73774. https://doi.org/10.1371/journal.pone.0073774 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0073774</ArticleId>
            <ArticleId IdType="pubmed">24040065</ArticleId>
            <ArticleId IdType="pmc">3767611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Hou Z, Qiu M, et al. Risk factors for primary Sjogren syndrome-associated interstitial lung disease. J Thorac Dis. 2018;10(4):2108–17. https://doi.org/10.21037/jtd.2018.03.120 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/jtd.2018.03.120</ArticleId>
            <ArticleId IdType="pubmed">29850114</ArticleId>
            <ArticleId IdType="pmc">5949459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang R, Sun T, Song L, et al. Increased levels of serum galectin-3 in patients with primary Sjogren’s syndrome: associated with interstitial lung disease. Cytokine. 2014;69(2):289–93. https://doi.org/10.1016/j.cyto.2014.06.008 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2014.06.008</ArticleId>
            <ArticleId IdType="pubmed">24981072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palm O, Garen T, Berge Enger T, et al. Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data. Rheumatology (Oxford). 2013;52(1):173–9. https://doi.org/10.1093/rheumatology/kes311 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kes311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yazisiz V, Arslan G, Ozbudak IH, et al. Lung involvement in patients with primary Sjogren’s syndrome: what are the predictors? Rheumatol Int. 2010;30(10):1317–24. https://doi.org/10.1007/s00296-009-1152-8 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-009-1152-8</ArticleId>
            <ArticleId IdType="pubmed">19844720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menor Almagro R, Jurado Roger A, Rodriguez Gutierrez FJ, et al. Association of anti-Ro52, anti-Ro60 and anti-La antibodies with diagnostic, clinical and laboratory features in a referral hospital in Jerez, Spain. Reumatol Clin. 2016;12(5):256–62. https://doi.org/10.1016/j.reuma.2015.10.010 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.reuma.2015.10.010</ArticleId>
            <ArticleId IdType="pubmed">26725021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aqrawi LA, Kvarnstrom M, Brokstad KA, et al. Ductal epithelial expression of Ro52 correlates with inflammation in salivary glands of patients with primary Sjogren’s syndrome. Clin Exp Immunol. 2014;177(1):244–52. https://doi.org/10.1111/cei.12341 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.12341</ArticleId>
            <ArticleId IdType="pubmed">24673429</ArticleId>
            <ArticleId IdType="pmc">4089173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao H, Zou YD, Zhang XW, et al. Interstitial Lung disease in non-sicca onset primary Sjogren’s syndrome: a large-scale case-control study. Int J Rheum Dis. 2018;21(7):1423–9. https://doi.org/10.1111/1756-185X.13334 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1756-185X.13334</ArticleId>
            <ArticleId IdType="pubmed">29968329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimura T, Ishii Y, Yoh K, et al. Overexpression of the transcription factor Gata-3 enhances the development of pulmonary fibrosis. Am J Pathol. 2006;169(1):96–104. https://doi.org/10.2353/ajpath.2006.051160 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2006.051160</ArticleId>
            <ArticleId IdType="pubmed">16816364</ArticleId>
            <ArticleId IdType="pmc">1698754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papiris SA, Kollintza A, Kitsanta P, et al. Relationship of Bal and lung tissue Cd4+ and Cd8+ T lymphocytes, and their ratio in idiopathic pulmonary fibrosis. Chest. 2005;128(4):2971–7. https://doi.org/10.1378/chest.128.4.2971 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.128.4.2971</ArticleId>
            <ArticleId IdType="pubmed">16236974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meloni F, Solari N, Cavagna L, et al. Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. Clin Exp Rheumatol. 2009;27(5):765–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19917158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pignatti P, Brunetti G, Moretto D, et al. Role of the chemokine receptors Cxcr3 and Ccr4 in human pulmonary fibrosis. Am J Respir Crit Care Med. 2006;173(3):310–7. https://doi.org/10.1164/rccm.200502-244OC .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.200502-244OC</ArticleId>
            <ArticleId IdType="pubmed">16239626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi L, Fu Q, Chen N, et al. Angiopoietin-like protein 2 as a novel marker for patients with primary Sjogren’s syndrome-related interstitial lung disease. Clin Exp Med. 2020;20(3):393–9. https://doi.org/10.1007/s10238-020-00623-6 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10238-020-00623-6</ArticleId>
            <ArticleId IdType="pubmed">32253547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izumi Y, Ida H, Huang M, et al. Characterization of peripheral natural killer cells in primary Sjogren’s syndrome: impaired Nk cell activity and low Nk cell number. J Lab Clin Med. 2006;147(5):242–9. https://doi.org/10.1016/j.lab.2006.01.001 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lab.2006.01.001</ArticleId>
            <ArticleId IdType="pubmed">16697772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002;2(10):735–47. https://doi.org/10.1038/nri911 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri911</ArticleId>
            <ArticleId IdType="pubmed">12360212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyazaki H, Kuwano K, Yoshida K, et al. The perforin mediated apoptotic pathway in lung injury and fibrosis. J Clin Pathol. 2004;57(12):1292–8. https://doi.org/10.1136/jcp.2003.015495 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jcp.2003.015495</ArticleId>
            <ArticleId IdType="pubmed">15563670</ArticleId>
            <ArticleId IdType="pmc">1770527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luzina IG, Todd NW, Nacu N, et al. Regulation of pulmonary inflammation and fibrosis through expression of integrins alphavbeta3 and alphavbeta5 on pulmonary T lymphocytes. Arthritis Rheum. 2009;60(5):1530–9. https://doi.org/10.1002/art.24435 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.24435</ArticleId>
            <ArticleId IdType="pubmed">19404954</ArticleId>
            <ArticleId IdType="pmc">2838614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gauldie J, Bonniaud P, Sime P, et al. Tgf-Beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans. 2007;35(Pt 4):661–4. https://doi.org/10.1042/BST0350661 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BST0350661</ArticleId>
            <ArticleId IdType="pubmed">17635115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Mo H, Zhu M, et al. Effect of cyclophosphamide on cytokines in patients with primary Sjogren’s syndrome-associated interstitial lung disease in South China. Rheumatol Int. 2013;33(6):1403–7. https://doi.org/10.1007/s00296-012-2561-7 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-012-2561-7</ArticleId>
            <ArticleId IdType="pubmed">23143555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polihronis M, Tapinos NI, Theocharis SE, et al. Modes of epithelial cell death and repair in Sjogren’s syndrome (Ss). Clin Exp Immunol. 1998;114(3):485–90. https://doi.org/10.1046/j.1365-2249.1998.00705.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2249.1998.00705.x</ArticleId>
            <ArticleId IdType="pubmed">9844061</ArticleId>
            <ArticleId IdType="pmc">1905140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suarez A, Lopez P, Gomez J, et al. Enrichment of Cd4+ Cd25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis. 2006;65(11):1512–7. https://doi.org/10.1136/ard.2005.049924 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2005.049924</ArticleId>
            <ArticleId IdType="pubmed">16606650</ArticleId>
            <ArticleId IdType="pmc">1798359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitley NT, Day MJ. Immunomodulatory drugs and their application to the management of canine immune-mediated disease. J Small Anim Pract. 2011;52(2):70–85. https://doi.org/10.1111/j.1748-5827.2011.01024.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1748-5827.2011.01024.x</ArticleId>
            <ArticleId IdType="pubmed">21265846</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
